We are live on
!
Find out more
GPC
Guardian Point Capital Portfolio holdings
AUM
$243M
1-Year Est. Return
22.43%
This Fund
S&P 500
This Quarter
Est. Return
-0.82%
1 Year Est. Return
+22.43%
3 Year Est. Return
+128.36%
5 Year Est. Return
+149.01%
10 Year Est. Return
+929.1%
AUM
$431M
AUM Growth
-$9.59M
(-2.2%)
Cap. Flow
-$4.88M
Cap. Flow
% of AUM
-1.13%
Top 10 Holdings %
Top 10 Hldgs %
79.98%
Holding
22
New
3
Increased
–
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acumen Pharmaceuticals
ABOS
|
+$8.32M |
| 2 |
ClearPoint Neuro
CLPT
|
+$4.31M |
| 3 |
Roblox
RBLX
|
+$4.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SS&C Technologies
SSNC
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 44.94% |
| 2 | Financials | 27.39% |
| 3 | Consumer Discretionary | 9.42% |
| 4 | Industrials | 6.77% |
| 5 | Healthcare | 3.62% |
Similar funds
W
VG
IFO
EW
MA
HBS
HCM
SC
Guardian Point Capital's Q3 2021 Portfolio in Review
As of Q3 2021, Guardian Point Capital held 22 positions worth $431M, down 2.2% from $441M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Guardian Point Capital's Q3 2021 filing shows 3 new and 1 closed positions. Its largest new stake was Acumen Pharmaceuticals: 500,000 shares worth $7.43M. The largest sale was SS&C Technologies, an estimated $21.6M.
By sector, the portfolio is most concentrated in Communication Services at 45% of assets, up from 44% a quarter earlier, followed by Financials and Consumer Discretionary.
- Guardian Point Capital's largest Q3 2021 buy was Acumen Pharmaceuticals: 500,000 shares worth $7.43M.
- Guardian Point Capital fully exited SS&C Technologies in Q3 2021, selling an estimated $21.6M.
- Guardian Point Capital's ten largest holdings make up 80% of its $431M portfolio in Q3 2021.
- Guardian Point Capital opened 3 new positions and closed 1 in Q3 2021.
- Guardian Point Capital's portfolio value fell 2.2% quarter-over-quarter to $431M.
Based on Guardian Point Capital's 13F filing for Q3 2021, filed 15 Nov 2021.